Board MeetingOutcome of Board Meeting
Nectar Lifesciences' board approved Q1 consolidated results, reporting a ₹15.40 Cr loss due to investment volatility.
Nectar Lifesciences LimitedNECLIFE · Filed with the exchange
Dr. Gunmala Suri was appointed as an Additional Director.
The 31st AGM is scheduled for Sept 18 as the company re-focuses on real estate ventures.
No comments yet. Be the first.